Trials / Completed
CompletedNCT02825563
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
Phase I Additional Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to further study the pharmacokinetic characteristics of Anlotinib in Advanced Cancer Patients with High Fat Diet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | in the fasting state |
| DRUG | Anlotinib | in the high fat diet |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2018-08-15
- Completion
- 2018-08-15
- First posted
- 2016-07-07
- Last updated
- 2019-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02825563. Inclusion in this directory is not an endorsement.